CN1053794A - 两性霉素b的纯化方法与组合物 - Google Patents
两性霉素b的纯化方法与组合物 Download PDFInfo
- Publication number
- CN1053794A CN1053794A CN90100998A CN90100998A CN1053794A CN 1053794 A CN1053794 A CN 1053794A CN 90100998 A CN90100998 A CN 90100998A CN 90100998 A CN90100998 A CN 90100998A CN 1053794 A CN1053794 A CN 1053794A
- Authority
- CN
- China
- Prior art keywords
- amphotericin
- water
- methylene dichloride
- composition
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 title claims abstract description 55
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 title claims abstract description 53
- 229960003942 amphotericin b Drugs 0.000 title claims abstract description 53
- 239000000203 mixture Substances 0.000 title claims description 23
- 238000000746 purification Methods 0.000 title description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 45
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims abstract description 31
- 238000000034 method Methods 0.000 claims abstract description 28
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims abstract description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 19
- 238000002425 crystallisation Methods 0.000 claims abstract description 9
- 230000008025 crystallization Effects 0.000 claims abstract description 7
- 239000002253 acid Substances 0.000 claims description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- 239000000284 extract Substances 0.000 claims description 9
- 239000002178 crystalline material Substances 0.000 claims description 6
- 239000002002 slurry Substances 0.000 claims description 6
- 239000013078 crystal Substances 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 2
- 238000005267 amalgamation Methods 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 239000011877 solvent mixture Substances 0.000 claims 1
- 239000002904 solvent Substances 0.000 abstract description 7
- 239000000047 product Substances 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- 239000007864 aqueous solution Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 4
- 229930183010 Amphotericin Natural products 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 229940009444 amphotericin Drugs 0.000 description 2
- 238000001354 calcination Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- SWXVUIWOUIDPGS-UHFFFAOYSA-N diacetone alcohol Natural products CC(=O)CC(C)(C)O SWXVUIWOUIDPGS-UHFFFAOYSA-N 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 229960004418 trolamine Drugs 0.000 description 2
- 241000187747 Streptomyces Species 0.000 description 1
- 241000122969 Streptomyces nodosus Species 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000002657 fibrous material Substances 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 150000004291 polyenes Chemical class 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- VGTPCRGMBIAPIM-UHFFFAOYSA-M sodium thiocyanate Chemical compound [Na+].[S-]C#N VGTPCRGMBIAPIM-UHFFFAOYSA-M 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
用一种独特的含有甲醇、二甲基甲酰胺、二氯甲
烷和水的四溶剂系统,提供一种改进的用于纯化与结
晶两性霉素B的方法。
Description
本发明涉及一种用于纯化与结晶两性霉素B的方法及组合物。
两性霉素B,一种有效的抗真菌剂,是一类已知多烯大环内酯抗菌素化合物中的一员。这些化合物的特征为有一个大的内酯环,该环含有一条共轭双键链。
两性霉素B及其由结节链霉菌Streptomyces nodosus制备的方法已被Dutcher等人在1959年10月13日批准的2,908,611号美国专利中公开。两性霉素B的结构已知为
由Dutcher等人公开的两性霉素的提取与结晶方法包括:
a.在带有一种酸的乙醇中将两性霉素的粗制品调成浆,然后用强碱中和;或
b.用二甲基甲酰胺将两性霉素粗制品调成浆,并用醇的水溶液或酮的水溶液处理。
michel等人在4,177,265号美国专利中公开了利用一种增溶介质纯化两性霉素B的方法,该介质含有碘化钠或硫氰酸钠以及丙酮或甲醇。使用这些介质中的任何一种可以大大增进两性霉素B的溶解度,而两性霉素B在丙酮或甲醇中的溶解度是受限的。
已经发现了用于纯化两性霉素B的新的方法和组合物,获得稳定产率的,高度结晶的产品。
根据本发明,公开了一种新的适于纯化两性霉素B的可获得稳定高产率的结晶物质的方法与结晶组合物。这种新的两性霉素B组合物含有溶于甲醇、二甲基甲酰胺、二氯甲烷和水的溶液中的两性霉素B。这种新的方法包括将粗制的、部分纯的或含杂质的两性霉素B溶于甲醇、二甲基甲酰胺和一种酸的溶液中,从提取混合物中分离出不溶成分,将纯的提取物与二氯甲烷和水的混合溶剂合并,使两性霉素B结晶,并回收结晶产物。
已经发现通过使用本方法的四溶剂系统,可以大大改进制备两性霉素B方法的连贯性以及产物的结晶性质。这种四溶剂系统包括最初溶解两性霉素B的二甲基甲酰胺和甲醇,以及将初始溶液过滤后所加入的二氯甲烷和水。所得到的两性霉素B结晶组合物含有溶于这四种溶剂中的两性霉素B和一种可与两性霉素B形成盐的酸。此外还发现当纯化、结晶、过滤、洗涤后,如果将产物干燥到使其保持至少2%(重量)的水、最好是约2-6%(重量)的水,可以获得更稳定的结晶物质。
下表说明了本发明方法的优点。表中所示为按照Dutcher等人在2,908,611号美国专利中描述的方法制备的两性霉素B与按照本发明方法制备的两性霉素B的比较。对各个产品的微生物效能、产率、纯度(通过产物灼烧后的残渣测量)以及稳定性进行测量。
微生物效能 产率 纯度 稳定性
(灼烧 (活性损失
残渣) /年)5℃
先有技术方法 884mcg/mg 80% 2.5% 10-15%
(重量)
本发明方法 1000mcg/mg 97% <0.1% <5%
(重量)
虽然还不知道发生这些改善的准确机制,但是可以确信,加至两性霉素B、甲醇和二甲基甲酰胺中的二氯甲烷和水增强了结晶结构,并因此增加了所生成的两性霉素B的微生物活性、纯度以及稳定性。
在该纯化方法中用作起始物质的两性霉素B可以包括粗制的、部分纯化的或含有杂质的两性霉素B。所谓“含有杂质的两性霉素B”是指含有物理杂质,例如杂污物颗粒、纤维状物质及其它可导致两性霉素B不适于药用的颗粒成份。
本方法中,第一步是通过将两性霉素B按任何次序悬浮于甲醇和二甲基甲酰胺的混合物中,并向其中加入酸,以提取两性霉素B起始物质。这种酸可以是任何容易与两性霉素B形成盐的酸,如柠檬酸、盐酸、硫酸等。温度不是关键的,但是最好是调节这样形成的混合物的温度到大约15-20℃下进行萃取,并搅拌直至两性霉素B的起始物质溶解。
应用本技术领域众所周知的方法分离该提取混合物。最好是使用过滤的方法将不溶物与两性霉素B提取物分离。
然后将纯化的两性霉素B提取物与二氯甲烷和水的混合溶剂合并。温度与加入二氯甲烷和水的顺序不是关键的,当然最好是将水冷却至约5-10℃。用一种碱的水溶液,例如三乙醇胺水溶液或任何其它合适的碱将混合物的pH值调至大约5-7,最好是约为6。该混合物沉淀出非晶形产物,并且所获得的这种浆料(非晶形产物和溶剂的)提供了一个合适的环境,促使两性霉素B转化成为结晶物质。
通过在约40℃-60℃、最好是在约45℃至约55℃加热,这种非晶形两性霉素B的浆料转变成为结晶物质。不是必要的,也可以向此浆料中加入少量晶种以加速结晶。
应用常规方法,例如离心或过滤,回收结晶的两性霉素B。可以用适当的溶剂洗涤所分离出的物质,如果需要可预先将其干燥。最好将分离出的物质干燥,使其保持至少2%(重量),最好是2-6%(重量)的水。用于洗涤步骤的典型溶剂为丙酮、丙酮与水的混合物、甲醇、甲醇与水的混合物、水或其混合物。
实施上面所述方法的操作条件可以选择在例如产生无菌产物的方式中。
通过下面的实施例将进一步描述本发明,但不意味被其中细节所限制。
例1
向约565升甲醇中加入约10BK(基本千克,即纯的活性物质的千克)两性霉素B和225升二甲基甲酰胺。加入约18.5KG水合柠檬酸(或等当量的无水酸)。将混合物保持在15-20℃,直至进料基本溶解。然后将此浓溶液过滤澄清。
接着,向该溶液中加入约140升的二氯甲烷。加入约225升冷却至5-10℃的水。然后将PH值调至约为6,使两性霉素B沉淀。使用40%V/V的三乙醇胺水溶液调节PH值。然后将所得到的浆料加热至44-46℃约30分钟。当进行显微观察测定,该产物已结晶时,将混合物在2-3小时内冷却至约10℃。然后过滤分离出纯化的产物,并用约85升冷却的40%V/V甲醇水溶液洗涤。将湿的滤饼在约140升丙酮中调成浆。过滤后,用约28升丙酮洗涤滤饼,然后干燥至2%-6%的含水量。回收的两性霉素B约为9.7BK。
Claims (10)
1、一种两性霉素B组合物,其中含有溶于由甲醇、二甲基甲酰胺、二氯甲烷和水组成的溶液中的两性霉素B和一种可与所述两性霉素B形成盐的酸。
2、如权利要求1的组合物,其中进一步含有一种适合于将所述组合物的PH值调至约5-7的试剂。
3、一种纯化与结晶两性霉素B的方法,其中包括:
a.在甲醇、二甲基甲酰胺及可与所述两性霉素B形成盐的酸中形成两性霉素B的溶液;
b.将不溶物与两性霉素B提取物分离;
c.将所述两性霉素B提取物与含有二氯甲烷和水的溶剂混合物合并;
d.调节所产生合并液的PH值到5-7;
e.加热所述的浆料以加快结晶物质形成;以及:
f.回收结晶的两性霉素B。
4、如权利要求3的方法,其中回收结晶物质按下述步骤进行:
ⅰ.从剩余的溶液中分离在步骤(e)中形成的结晶物质;
ⅱ.洗涤并干燥分离出的晶体,其中将晶体干燥至保持2-6%(重量)的水。
5、按照权利要求3的方法,其中步骤(a)在约15-20℃进行。
6、按照权利要求3的方法,其中在步骤(a)中所述两性霉素B、甲醇和二甲基甲酰胺被混合在一起,然后加入所述的柠檬酸。
7、按照权利要求3的方法,其中所述分离是通过过滤完成的。
8、按照权利要求3的方法,其中在步骤(c)中所述的二氯甲烷被加至所述的提取物中,然后将在约5-10℃的温度下的水加至所述二氯甲烷和所述提取物中。
9、按照权利要求3的方法,其中在步骤(d)中合并液的PH值被调至约为6。
10、按照权利要求3的方法,其中所述非晶形两性霉素B被加热至约40℃-60℃,使其转化成为结晶两性霉素B。
Priority Applications (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/113,790 US4902789A (en) | 1987-10-27 | 1987-10-27 | Process and composition for the purification of amphotericin B |
| GB9000357A GB2239653B (en) | 1987-10-27 | 1990-01-08 | Process and composition for the purification of amphotericin b |
| CA002007367A CA2007367C (en) | 1987-10-27 | 1990-01-09 | Process and composition for the purification of amphotericin b |
| HU90124A HU205768B (en) | 1987-10-27 | 1990-01-12 | Process for purifying amphotericin b |
| FR909000722A FR2657260B1 (fr) | 1987-10-27 | 1990-01-23 | Procede et composition permettant de purifier l'amphotericine b.. |
| DE4002351A DE4002351A1 (de) | 1987-10-27 | 1990-01-26 | Verfahren und zusammensetzung zur reinigung vom amphotericin b |
| CN90100998A CN1029617C (zh) | 1987-10-27 | 1990-01-31 | 纯化与结晶两性霉素b的方法 |
| JP2025894A JPH03240793A (ja) | 1987-10-27 | 1990-02-05 | アンフォテリシンbの精製方法および組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/113,790 US4902789A (en) | 1987-10-27 | 1987-10-27 | Process and composition for the purification of amphotericin B |
| CA002007367A CA2007367C (en) | 1987-10-27 | 1990-01-09 | Process and composition for the purification of amphotericin b |
| CN90100998A CN1029617C (zh) | 1987-10-27 | 1990-01-31 | 纯化与结晶两性霉素b的方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1053794A true CN1053794A (zh) | 1991-08-14 |
| CN1029617C CN1029617C (zh) | 1995-08-30 |
Family
ID=36754226
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN90100998A Expired - Fee Related CN1029617C (zh) | 1987-10-27 | 1990-01-31 | 纯化与结晶两性霉素b的方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US4902789A (zh) |
| JP (1) | JPH03240793A (zh) |
| CN (1) | CN1029617C (zh) |
| CA (1) | CA2007367C (zh) |
| DE (1) | DE4002351A1 (zh) |
| FR (1) | FR2657260B1 (zh) |
| GB (1) | GB2239653B (zh) |
| HU (1) | HU205768B (zh) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102746352A (zh) * | 2011-04-20 | 2012-10-24 | 上海新先锋药业有限公司 | 一种治疗深部真菌感染药物的纯化工艺 |
| CN112175029A (zh) * | 2019-07-01 | 2021-01-05 | 刘力 | 抗真菌的大环多烯类新化合物 |
| CN114605484A (zh) * | 2020-12-09 | 2022-06-10 | 上海上药新亚药业有限公司 | 一种获得两性霉素b新晶型的纯化方法 |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8404217B2 (en) * | 2000-05-10 | 2013-03-26 | Novartis Ag | Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use |
| US8648050B2 (en) * | 2002-10-03 | 2014-02-11 | University Of Mississippi | Methods and formulations for reducing amphotericin B treatment side effects |
| EP1551423B1 (en) * | 2002-10-03 | 2008-04-09 | University of Mississippi | Compositions comprising amphotericin B comprising less than 4 % impurities |
| EP1983827A4 (en) | 2006-02-01 | 2013-07-10 | Stuart L Weg | USE OF ANTIFUNGAL COMPOSITIONS FOR TREATING UPPER GASTROINTESTINAL CONDITIONS |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2908611A (en) * | 1954-12-28 | 1959-10-13 | Olin Mathieson | Amphotericin b, its production, and its salts |
| FR2173632A1 (en) * | 1971-02-04 | 1973-10-12 | Le N Iss | Purificn of amfotericin b - in dmf soln by adding water acidifying filtering adding water,making alkaline and washing |
| CH556879A (de) * | 1971-04-23 | 1974-12-13 | Le Nii Antibiotikov | Verfahren zur gewinnung und chemischen reinigung von amphoterizin b. |
| US3965090A (en) * | 1973-03-05 | 1976-06-22 | E. R. Squibb & Sons, Inc. | Amphotericin complexes |
| US4049898A (en) * | 1973-03-05 | 1977-09-20 | E. R. Squibb & Sons, Inc. | Amphotericin complexes containing oxalic acid and calcium |
| DE2500731A1 (de) * | 1975-01-10 | 1976-07-15 | Magg | Einrichtung zum spannen von tauen, seilen oder draehten |
| US4054734A (en) * | 1975-03-03 | 1977-10-18 | E. R. Squibb & Sons, Inc. | Amphotericin complexes containing citric acid and calcium |
| US4177265A (en) * | 1977-03-02 | 1979-12-04 | E. R. Squibb & Sons, Inc. | Process for the purification of amphotericin B and A solubilizing media useful in that process |
| US4308375A (en) * | 1980-10-06 | 1981-12-29 | E. R. Squibb & Sons, Inc. | Method for purifying water-insoluble polyene antibiotics |
-
1987
- 1987-10-27 US US07/113,790 patent/US4902789A/en not_active Expired - Lifetime
-
1990
- 1990-01-08 GB GB9000357A patent/GB2239653B/en not_active Expired - Fee Related
- 1990-01-09 CA CA002007367A patent/CA2007367C/en not_active Expired - Fee Related
- 1990-01-12 HU HU90124A patent/HU205768B/hu not_active IP Right Cessation
- 1990-01-23 FR FR909000722A patent/FR2657260B1/fr not_active Expired - Lifetime
- 1990-01-26 DE DE4002351A patent/DE4002351A1/de not_active Withdrawn
- 1990-01-31 CN CN90100998A patent/CN1029617C/zh not_active Expired - Fee Related
- 1990-02-05 JP JP2025894A patent/JPH03240793A/ja active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102746352A (zh) * | 2011-04-20 | 2012-10-24 | 上海新先锋药业有限公司 | 一种治疗深部真菌感染药物的纯化工艺 |
| CN102746352B (zh) * | 2011-04-20 | 2016-03-30 | 上海新亚药业有限公司 | 一种治疗深部真菌感染药物的纯化工艺 |
| CN112175029A (zh) * | 2019-07-01 | 2021-01-05 | 刘力 | 抗真菌的大环多烯类新化合物 |
| CN114605484A (zh) * | 2020-12-09 | 2022-06-10 | 上海上药新亚药业有限公司 | 一种获得两性霉素b新晶型的纯化方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| HU900124D0 (en) | 1990-03-28 |
| FR2657260B1 (fr) | 1992-04-24 |
| HUT56377A (en) | 1991-08-28 |
| CN1029617C (zh) | 1995-08-30 |
| DE4002351A1 (de) | 1991-08-01 |
| CA2007367A1 (en) | 1991-07-09 |
| US4902789A (en) | 1990-02-20 |
| GB9000357D0 (en) | 1990-03-07 |
| JPH03240793A (ja) | 1991-10-28 |
| CA2007367C (en) | 2000-03-14 |
| FR2657260A1 (fr) | 1991-07-26 |
| GB2239653A (en) | 1991-07-10 |
| GB2239653B (en) | 1993-06-23 |
| HU205768B (en) | 1992-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| USRE34672E (en) | Pharmaceutical composition containing a stable modification of torasemide | |
| CN1029617C (zh) | 纯化与结晶两性霉素b的方法 | |
| DE60104103T2 (de) | Verfahren zur herstellung von hochkristallinem natrium cefoperazon | |
| DE60017399T2 (de) | Diphosphat-salz von einem 4"-substitutierte-9-deoxo-9a-aza-9a-homoerythromyin-derivat und seine pharmazeutische zubereitung | |
| US4177265A (en) | Process for the purification of amphotericin B and A solubilizing media useful in that process | |
| US2729642A (en) | Water soluble salts of 8-(para-aminobenzyl) caffeine and method for their preparation | |
| US3127315A (en) | Hypocholesterolemic agent m- | |
| US3061515A (en) | Methane sulfonates of telomycins | |
| Irvine et al. | CXXX.—Partially methylated glucoses. Part III. Monomethyl glucose | |
| KR0137458B1 (ko) | 암포테리신 b의 정제 방법 및 그를 위한 조성물 | |
| KR960003618B1 (ko) | 4-카르바모일-1-β-D-리보푸라노실 이미다졸륨-5-올레이트 무수결정 | |
| HK886A (en) | PROCESS FOR THE RESOLUTION OF d,l 2-(6-METHOXY-2-NAPHTHYL)PROPIONIC ACID; A MIXTURE OF THE SALTS OF THESE d AND l ACIDS; A PHARMACEUTICAL COMPOSITION CONTAINING A SALT OF THE d ACID; A SALT OF THE d ACID | |
| EP0101170B1 (en) | Process for the manufacture of sodium cefoperazone | |
| US2865807A (en) | Nystatin purification | |
| HU176213B (en) | Process for preparing a new crystallic modification of the sodium salt of 7beta-cyanacetylamino-3-acetoxymethyl-cef-3-em-4-carboxylic acid | |
| US6040445A (en) | Acyclovir dihydrate sodium salt and the preparation thereof | |
| US6984725B2 (en) | Method for the separation of triglycoalkaloids | |
| IE64233B1 (en) | Process and composition for the purification of amphotericin b | |
| US2876228A (en) | Recovery of rescinnamine | |
| CA1221367A (en) | Fine crystalline isoxicam | |
| DE2416709C2 (de) | Kristallines Mononatriumsalz von cyclischem N↑6↑-2'-O-Dibutyryladenosin-3',5'-monophosphat und Verfahren zu seiner Herstellung | |
| HU217067B (hu) | Eljárás kristályos lorakarbef-monohidrát előállítására | |
| US4370485A (en) | Germaazaspirodiones | |
| US3911113A (en) | Recrystallization process for the purification of nystatin | |
| FI78454B (fi) | Foerfarande foer framstaellning av zinkglukonattrihydrat. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C15 | Extension of patent right duration from 15 to 20 years for appl. with date before 31.12.1992 and still valid on 11.12.2001 (patent law change 1993) | ||
| OR01 | Other related matters | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |